Increased Persistency in Medication Use by US Medicare Beneficiaries with Diabetes is Associated with Lower Hospitalization Rates and Cost Savings
- Bruce C. Stuart, PhD1,
- Linda Simoni-Wastila, PhD1,
- Lirong Zhao, MS1,
- Jennifer T. Lloyd, MA (jlloyd{at}rx.umaryland.edu)1 and
- Jalpa A Doshi, PhD2
- 1University of Maryland Baltimore, Peter Lamy Center on Drug Therapy and Aging
- 2University of Pennsylvania, Department of General Internal Medicine
Abstract
Objective: Assess the relationship between annual fills for antidiabetic medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and lipid lowering agents on hospitalization and Medicare spending for beneficiaries with diabetes.
Research design and methods: Using Medicare Current Beneficiary Survey data from 1997-2004, we identified 7,441 community dwelling beneficiaries with diabetes who contributed 14,317 person-years of data for the analysis. We used multivariate regression analysis to estimate the impact of persistency in medication fills on hospitalization risk, hospital days, and Medicare spending.
Results: For users of older oral antidiabetic agents, ACE inhibitors, ARBs, and statins, each additional prescription fill was associated with significantly lower risk of hospitalization, fewer hospital days, and lower Medicare spending.
Conclusions: These results suggest an economic case for promoting greater persistency in use of drugs with approved indications by Medicare beneficiaries with diabetes, but additional research is needed to corroborate the study's cross-sectional findings.
Footnotes
-
- Received July 14, 2008.
- Accepted January 11, 2009.
- Copyright © American Diabetes Association
